Stelis Biopharma Names Mark W. Womack as its New CEO

Mark takes over as CEO immediately and will be based at the Stelis headquarters in Bengaluru, India.

FREMONT, CA: Stelis Biopharma Limited, a vertically integrated biopharma and vaccines Company and the biotech branch of Strides Pharma Science Limited, appoints Mark W. Womack (Mark) as its new Chief Executive Officer (CEO).

Mark is also the designated Managing Director (MD) and will subsequently be introduced to the board, subject to the requisite regulatory clearances and processes. Mark will provide strong leadership as the Company's CEO and MD, driving an aggressive growth and profitability strategy for Stelis in its business streams, including global Contract Development and Manufacturing Organization (CDMO) services and the development of the company's biosimilars pipeline, and integrated vaccines play. He will be in charge of the company's overall strategy and provide the essential direction and active leadership to R&D, manufacturing, business development, and commercial operations.

Commenting on the development, Arun Kumar, Founder, Strides Group, says, "We are delighted to onboard Mark as the new CEO of Stelis. Stelis stands on the cusp of a transition to become a globally recognized biopharmaceutical company while targeting significant growth in the coming years. Mark's strong background in commercial leadership, rich management consulting experience, and network within the biotech CDMO space make him exceptionally well suited to drive this transition for Stelis.  

We are confident that together Mark and his leadership team will take Stelis through the next level of growth, profitability and industry-leading reputation."

Mark is an organization builder who has a proven track record of producing remarkable performance and development in previous jobs. Before joining Stelis, Mark was the Chief Business Officer (CBO) for AGC Biologics (AGC), one of the world's largest global biopharmaceutical CDMOs. In his role at AGC, Mark oversaw a roughly threefold growth in new sales in just two years, as well as the acquisition of the majority of the world's top large pharma businesses. Mark previously supervised the global integration of three former CDMOs united to establish AGC Biologics, leveraging his management consultancy background.

Mark has over 25 years of experience as a management consulting industry leader and C-level client adviser, directing large-scale company transformations and guiding many of the world's most prestigious organizations to record highs in revenue and profit. During this time, he held the position of Chief Operating Officer for two worldwide management consulting firms.

Before joining the management consulting sector, Mark managed several US Navy units to unparalleled success, including serving as a battle center leader aboard a destroyer class ship. Mark is a US citizen located in Bengaluru, India, at the company's corporate headquarters.